Treatment of seasonal or year-round allergic rhinitis in adults and children aged 2 years and older. Preventive treatment of allergic rhinitis of medium and severe course is recommended to start 4 weeks before the expected start of the dusting season. As an auxiliary therapeutic agent in the treatment of acute episodes of sinusitis with antibiotics in adults (including elderly patients) and children over 12 years of age. Treatment of symptoms of acute rhinosinusitis without signs of severe bacterial infection in adults and children over 12 years of age. Treatment of nasal polyps and related symptoms, including nasal congestion and loss of smell, in patients aged 18 and over.
Glenspray 60 doses Storage
active substance: mometasone furoate;
1 dose contains mometasone furoate monohydrate equivalent to mometasone furoate 50 μg;
excipients: microcrystalline cellulose and sodium carboxymethylcellulose; glycerin; citric acid, monohydrate; sodium citrate; polysorbate 80; benzalkonium chloride; water for injections.
Glenspray 60 doses Dosage form
Nasal spray, dosed; suspension.
Main physical and chemical properties: white or almost white translucent viscous suspension.
Anti-edema and other drugs for topical use in diseases of the nasal cavity. Corticosteroids. ATX code R01A D09.
Glenspray 60 doses Pharmacological properties
Mometasone furoate is a synthetic topical corticosteroid with pronounced anti-inflammatory action. Corticosteroids show a wide range of effects on various cells, namely heparinocytes, eosinophils, neutrophils, macrophages, lymphocytes, as well as inflammatory mediators (histamine, eicosanoids, leukotrienes and cytokines). The mechanism of anti-inflammatory and anti-allergic action of mometasone furoate is mainly related to its ability to inhibit the release of mediators of allergic reactions.
Mometasone furoate significantly inhibits the release of leukotrienes from leukocytes in patients with allergies. In studies on cell cultures of mometasone furoate showed a pronounced activity in inhibiting the synthesis and secretion of IL-1, IL-5, IL-6 and TNFα, and it effectively inhibited leukotriene production. In addition, it is extremely active in inhibiting the synthesis of cytokines Th2, IL-4 and IL-5 from human CD4 + T cells.
Studies have shown that mometasone furoate as a nasal spray 50 μg / dose when applied topically reduces the level of some mediators of the early and late phase of the allergic reaction, reduces (compared with placebo) the level of histamine and eosinophilic cationic protein and reduces (compared to baseline) , neutrophils and adhesive proteins of epithelial cells.
The bioavailability of mometasone furoate when used as a nasal spray is <1% in blood plasma (according to data obtained using a sensitive method of quantification, the lower limit of quantification is 0.25 pg / ml). Mometasone furoate suspension is very poorly absorbed from the gastrointestinal tract, and the small amount that can be swallowed and absorbed undergoes active primary metabolism before excretion, mainly as metabolites in bile and in limited quantities in urine.
Treatment of seasonal or perennial allergic rhinitis in adults and children over 2 years of age. Preventive treatment of allergic rhinitis of moderate and severe course is recommended to begin 4 weeks before the expected start of the pollination season.
As an adjunct to the treatment of acute episodes of sinusitis with antibiotics in adults (including elderly patients) and children over 12 years of age.
Treatment of symptoms of acute rhinosinusitis without signs of severe bacterial infection in adults and children over 12 years of age.
Treatment of nasal polyps and related symptoms, including nasal congestion and olfactory loss, in patients over 18 years of age.
Hypersensitivity to mometasone furoate or to other components of the drug.
Untreated local infection of the nasal mucosa.
Nasal injury or recent nose surgery.